Is larotrectinib suitable for the treatment of advanced solid tumors?

Larotrectinib is a highly selective TRK inhibitor that mainly targets NTRK gene fusion-positive tumor cells. This type of gene fusion is a driver mutation found in many different types of solid tumors. Different from traditional treatment methods classified by site, larotrectinib uses a "tissue-independent" therapy. As long as the tumor has NTRK fusion, it is theoretically applicable regardless of the primary site. Therefore, it is considered to be one of the important breakthroughs in precision medicine.

In the treatment of advanced solid tumors, larotrectinib has particularly outstanding application prospects. Data from multiple clinical studies show that for advanced patients with NTRK fusion positivity, the objective response rate (ORR) of larotrectinib exceeds 75% and some patients can achieve durable remission or even significant tumor shrinkage. In addition, it also shows certain activity against central nervous system metastasis, especially providing new treatment options for patients with recurrence or metastasis who have failed traditional therapies.

The safety of larotrectinib is also relatively good. Common side effects such as fatigue, dizziness, nausea, etc. are mostly mild to moderate, and most patients can tolerate it well. Compared with the severe toxic reactions caused by chemotherapy or immunotherapy, larotrectinib has obvious advantages in improving the quality of life, so it is easier to maintain long-term use in the treatment of advanced solid tumors.

It should be noted that the prerequisite for the use of larotrectinib is that patients must undergo accurate detection of theNTRK fusion gene. Since NTRKfusion is relatively rare in general cancer patients, there are still cost and technical barriers to widespread screening. Therefore, in clinical practice, it is recommended that patients with advanced, recurrent, and multi-line solid tumors who have failed multiple lines of treatment, especially those who are younger or have rare pathological types, should be given priority for genetic testing to evaluate whether they have the opportunity to benefit from larotrectinib treatment.

Reference materials:https://www.drugs.com/